Patients were randomized to receive (i) monthly IV-cyclophosphamide, (ii) monthly IV methylprednisolone, or (iii) both. The study is now closed to new entrants. Rate of progression to renal failure, requirements for re-treatment, and drug toxicities are being assessed. Clear-cut differences have yet to emerge for the entire group of patients completing 3 years of study.

Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
1992
Total Cost
Indirect Cost
Name
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Department
Type
DUNS #
City
State
Country
United States
Zip Code